CalciMedica (CALC) Stock Price, News & Analysis

Company Overview

CalciMedica, Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients.

CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.

Key Stats

• Today's Range: $0.93 to $1.05
• 50-Day Range: $0.56 to $1.06
• 52-Week Range: $0.46 to $7.20
• Volume: 403,820 shs
• Average Volume: 3.53 million shs
• Market Capitalization: $15.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

CalciMedica Stock Analysis - MarketRank™

CalciMedica scored higher than 71% of companies evaluated by MarketBeat, and ranked 354th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

CalciMedica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

CalciMedica has a consensus price target of $10.00, representing about 935.8% upside from its current price of $0.97.

Amount of Analyst Coverage

CalciMedica has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CalciMedica are expected to decrease in the coming year, from ($1.12) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CalciMedica is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CalciMedica is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.99% of the float of CalciMedica has been sold short.

Short Interest Ratio / Days to Cover

CalciMedica has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CalciMedica has recently increased by 91.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CalciMedica does not currently pay a dividend.

Dividend Growth

CalciMedica does not have a long track record of dividend growth.

News and Social Media

• Score: 4.7 / 5
• News Sentiment: 1.51

News Sentiment

CalciMedica has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CalciMedica this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CALC on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added CalciMedica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $199,178.00 in company stock, which represents 1.3058% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $199,178.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CalciMedica has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 7/03/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALC
• CIK: 1534133
• Web: www.graybug.vision
• Phone: 858-952-5500
• Fax: N/A
• Employees: 30
• Year Founded: 2007

Price Target and Rating

• Average Price Target for CalciMedica: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +935.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -863.40%
• Return on Assets: -144.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.61
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.46) per share
• Price / Book: -2.10

Miscellaneous

• Outstanding Shares: 15,800,000
• Free Float: 9,234,000
• Market Cap: $15.25 million
• Optionable: No Data
• Beta: 0.89